Female sexual dysfunction - PubMed (original) (raw)
Review
Female sexual dysfunction
Jennifer J Wright et al. Med Clin North Am. 2015 May.
Abstract
Female sexual dysfunction is a common patient concern. After providing an overview regarding the various types of female sexual dysfunction, we will focus on history taking and treatment options for desire, arousal, orgasm, and pain disorders. Testosterone therapy and management of selective serotonin reuptake inhibitor-associated sexual dysfunction are reviewed. Treatments for atrophic vaginitis are appraised. Patient cases lead the discussion, providing the reader with clinically relevant information.
Keywords: Atrophic vaginitis; Female sexual dysfunction; Hypoactive sexual desire disorder; SSRI-induced sexual dysfunction; Testosterone therapy.
Copyright © 2015 Elsevier Inc. All rights reserved.
Similar articles
- Efficacy of testosterone combined with a PDE5 inhibitor and testosterone combined with a serotonin (1A) receptor agonist in women with SSRI-induced sexual dysfunction. A preliminary study.
van Rooij K, Poels S, Worst P, Bloemers J, Koppeschaar H, Goldstein A, Olivier B, Tuiten A. van Rooij K, et al. Eur J Pharmacol. 2015 Apr 15;753:246-51. doi: 10.1016/j.ejphar.2014.10.061. Epub 2014 Nov 24. Eur J Pharmacol. 2015. PMID: 25460030 Clinical Trial. - Patient scenario: a 53-year-old woman with hypoactive sexual desire disorder.
Palacios S, Graziottin A. Palacios S, et al. Maturitas. 2009 Jun 20;63(2):164-8. doi: 10.1016/j.maturitas.2009.05.002. Epub 2009 May 31. Maturitas. 2009. PMID: 19487091 Review. - [Female sexual dysfunction: Drug treatment options].
Alcántara Montero A, Sánchez Carnerero CI. Alcántara Montero A, et al. Semergen. 2016 Jul-Aug;42(5):e33-7. doi: 10.1016/j.semerg.2016.02.008. Epub 2016 Mar 31. Semergen. 2016. PMID: 27041639 Review. Spanish. - Advances in pharmacotherapy for treating female sexual dysfunction.
Nappi RE, Cucinella L. Nappi RE, et al. Expert Opin Pharmacother. 2015 Apr;16(6):875-87. doi: 10.1517/14656566.2015.1020791. Epub 2015 Mar 2. Expert Opin Pharmacother. 2015. PMID: 25732267 Review. - Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine.
Kennedy SH, Eisfeld BS, Dickens SE, Bacchiochi JR, Bagby RM. Kennedy SH, et al. J Clin Psychiatry. 2000 Apr;61(4):276-81. doi: 10.4088/jcp.v61n0406. J Clin Psychiatry. 2000. PMID: 10830148
Cited by
- Pharmacotherapy for Sexual Dysfunction in Women.
Lee JH, Lee JE, Harsh V, Clayton AH. Lee JH, et al. Curr Psychiatry Rep. 2022 Feb;24(2):99-109. doi: 10.1007/s11920-022-01322-7. Epub 2022 Feb 1. Curr Psychiatry Rep. 2022. PMID: 35102537 Review. - Sexual Dysfunction and its Associated Factors After Delivery: Longitudinal Study in Iranian Women.
Banaei M, Moridi A, Dashti S. Banaei M, et al. Mater Sociomed. 2018 Oct;30(3):198-203. doi: 10.5455/msm.2018.30.198-203. Mater Sociomed. 2018. PMID: 30515059 Free PMC article. - The prevalence of sexual dysfunction among postpartum women on the East Coast of Malaysia.
Khalid NN, Jamani NA, Abd Aziz KH, Draman N. Khalid NN, et al. J Taibah Univ Med Sci. 2020 Sep 22;15(6):515-521. doi: 10.1016/j.jtumed.2020.08.008. eCollection 2020 Dec. J Taibah Univ Med Sci. 2020. PMID: 33318744 Free PMC article. - Flibanserin (Addyi): The First FDA-Approved Treatment for Female Sexual Interest/Arousal Disorder in Premenopausal Women.
English C, Muhleisen A, Rey JA. English C, et al. P T. 2017 Apr;42(4):237-241. P T. 2017. PMID: 28381915 Free PMC article. - Factors Associated with Postpartum Sexual Dysfunction in Spanish Women: A Cross-Sectional Study.
Hidalgo-Lopezosa P, Pérez-Marín S, Jiménez-Ruz A, López-Carrasco JC, Cubero-Luna AM, García-Fernández R, Rodríguez-Borrego MA, Liébana-Presa C, López-Soto PJ. Hidalgo-Lopezosa P, et al. J Pers Med. 2022 Jun 2;12(6):926. doi: 10.3390/jpm12060926. J Pers Med. 2022. PMID: 35743712 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical